Trial Profile
A Phase I Safety and Pharmacokinetic Study of Intravenous RTA 744 Injection in Patients With Recurrent, Progressive or Refractory Neoplastic Meningitis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Berubicin (Primary)
- Indications Meningeal carcinomatosis; Neoplastic meningitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biogen
- 26 May 2016 New trial record